期刊文献+

丙型肝炎治疗与靶向药物研究进展 被引量:2

原文传递
导出
出处 《中国药房》 CAS CSCD 北大核心 2008年第26期2063-2066,共4页 China Pharmacy
基金 云南省国际合作项目(2006GH07) 云南省应用基础研究项目(2007CO38M)
  • 相关文献

参考文献22

  • 1Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hep atltis C infections[J]. Curt Opin lnvestig Drugs ,2004, 5(8) : 838.
  • 2Carithers RL, Emerson SS. Therapy of hepatitis C: metaanalysis of inter feron alfa- 2b tr als[J] . Hep- atology, 1997,26(3 Suppl 1) :83S.
  • 3Watson J. Prospects for hepatitis C virus therapeutics : Levovirin and viramidine as improved derivatives of ribavirin[J ]. Curt Opin lnwestig Drugs, 2002,3(5) :680.
  • 4Fried MW, Shiffman M L, Reddy KR, et al. Peginterferon alfa 24 plus rihavirin for chronic hepatitis C virus infection[J ]. N Engl J Med, 2002,347(3) : 975.
  • 5袁孝蓉,安富荣.聚乙二醇化干扰素α-2a治疗病毒性肝炎新进展[J].中国药房,2006,17(5):387-389. 被引量:8
  • 6Lindsay KL, Trepo C, Heintges T, et al .A randomized, double blind trial comparing pegylated inlerferon alfa 2b to interferon alfa 2b as inilial treatment for chronic hepatitis C[J ]. Hepatology,,2001,34(2) :395.
  • 7刘君澜,白永敏,田庚善.复方甘草酸苷在肝病领域的应用进展[J].中国药房,2006,17(23):1828-1830. 被引量:18
  • 8Frecer V, Kabelac M, De Nardi P, et al. Structure - based design of inhibilors of NS3 serine protease of hep- atitis C virus[J] .Journal of Molecular Graphics and Modelling,2004,22(3) :209.
  • 9Llinas Brunet M, Bailey MD, Bolger G, et al. Structure - activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061[J] . J ivied Chem, 2004, 47(7) : 1 605.
  • 10Huang Z, Murray MG, Secrist JA. Recent development of therapeutics for chronic HCV infection[J]. Antiviral Research , 2006,71(2) : 351.

二级参考文献32

共引文献24

同被引文献98

  • 1詹林盛,饶林,彭剑淳,王会中,贾帅争,王全立.HCVIRES介导荧光素酶小鼠体内表达模型的建立[J].中华微生物学和免疫学杂志,2004,24(3):239-240. 被引量:5
  • 2谭文杰,张柯,阮力.丙型肝炎病毒(HCV)实验性疫苗的研究进展[J].中国生物工程杂志,2006,26(10):64-70. 被引量:10
  • 3李晓霞,肖会泉,罗日永.健脾补肾方治疗慢性丙型肝炎20例临床观察[J].新中医,2006,38(11):33-35. 被引量:5
  • 4张柯,阮力,谭文杰.抗HCV中和抗体的研究进展[J].细胞与分子免疫学杂志,2007,23(3):282-285. 被引量:4
  • 5Soriano V, Madejon A, Vispo E, et al. Emerging drugs for hepatitis C [J]. Expert Opin Emerg Drugs,2008,13(3) :1 - 19.
  • 6Tao W, Xu C, Ding Q, et al. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles [ J ]. Virology ,2009,395 ( 1 ) :67 - 76.
  • 7Keck ZY ,Li SH ,Xia J ,et al. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity [ J ]. J Virol, 2009, 83 (12) :6149 -6160.
  • 8Kapadia SB, Brideau - Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs[ J]. Proc Natl, Acad Sci USA ,2003,100:2014 - 2018.
  • 9Darke PL,Jacobs AR, Waxman L,et al. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides [ J ]. J Biol Chem, 1999, 274 (49) :34511 -34514.
  • 10Ciesek S, Steinmann E, Wedemeyer H, et at. Cyelosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A [ J]. Hepatology, 2009,50 ( 5 ) : 1638 - 1645.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部